Literature DB >> 10864603

Reduced cerebral blood flow in white matter in ischaemic leukoaraiosis demonstrated using quantitative exogenous contrast based perfusion MRI.

H S Markus1, D J Lythgoe, L Ostegaard, M O'Sullivan, S C Williams.   

Abstract

OBJECTIVE: White matter hypoperfusion may play a part in the pathogenesis of ischaemic leukoaraiosis, but demonstration of this requires a high resolution quantitative method of cerebral blood flow (CBF) measurement. Initial exogenous contrast based MRI methods only allowed measurement of relative cerebral blood volume (CBV) values, but more recently a mathematical approach has been developed which enables absolute regional CBF and CBV to be determined. This technique was applied to patients with ischaemic leukoaraiosis to determine whether reduced white matter CBF in this patient group could be demonstrated.
METHODS: Eight patients with ischaemic leukoaraiosis (radiological leukoaraiosis and clinical lacunar stroke), and nine age matched controls were studied. A spin echo echoplanar image sequence was used on a 1.5 Tesla MR system. An arterial input function was obtained from voxels placed over the middle cerebral arteries. Cerebral blood flow, CBV, and mean transit (MTT) maps were derived. Regions of interest were placed at standard positions in the white and grey matter and mean values of CBF, CBV, and MTT were compared between the two groups.
RESULTS: Mean (SD) white matter CBF was significantly reduced in patients by 38% (13.40 (4.87) v 21.74 (3.53) ml/min/ 100 g, p=0.002). Significant reductions in CBF were seen in all white matter regions. By contrast there was no reduction in CBF in any grey matter region. There was no significant difference in white matter CBV between cases and controls; mean values were lower in all white matter regions for patients but this did not reach significance for any region. By contrast mean grey matter CBV was significantly higher in patients than in controls. Mean MTT values were higher in all regions of grey and white matter in the patient group, but this only achieved significance for the superior white matter.
CONCLUSION: A quantitative MR perfusion method showed reduced white matter CBF in patients with ischaemic leukoaraiosis, but normal grey matter CBF. This is consistent with hypoperfusion playing a part in the pathogenesis of ischaemic leukoaraiosis. The absolute values of white matter and grey matter CBF obtained in the patient groups were very similar to those in previous PET studies, providing further evidence for the validity of the regional CBF measurements obtained using this quantitative MR perfusion technique. The high spatial resolution and lack of radioactive administration makes such techniques ideal for longitudinal studies in this condition.

Entities:  

Mesh:

Year:  2000        PMID: 10864603      PMCID: PMC1737001          DOI: 10.1136/jnnp.69.1.48

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  16 in total

1.  Cerebral blood flow and oxygen metabolism in patients with vascular dementia of the Binswanger type.

Authors:  H Yao; S Sadoshima; Y Kuwabara; Y Ichiya; M Fujishima
Journal:  Stroke       Date:  1990-12       Impact factor: 7.914

2.  Cerebral blood flow measurements by magnetic resonance imaging bolus tracking: comparison with [(15)O]H2O positron emission tomography in humans.

Authors:  L Ostergaard; P Johannsen; P Høst-Poulsen; P Vestergaard-Poulsen; H Asboe; A D Gee; S B Hansen; G E Cold; A Gjedde; C Gyldensted
Journal:  J Cereb Blood Flow Metab       Date:  1998-09       Impact factor: 6.200

3.  High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis.

Authors:  L Ostergaard; R M Weisskoff; D A Chesler; C Gyldensted; B R Rosen
Journal:  Magn Reson Med       Date:  1996-11       Impact factor: 4.668

4.  Leuko-araiosis.

Authors:  V C Hachinski; P Potter; H Merskey
Journal:  Arch Neurol       Date:  1987-01

5.  MR contrast due to intravascular magnetic susceptibility perturbations.

Authors:  J L Boxerman; L M Hamberg; B R Rosen; R M Weisskoff
Journal:  Magn Reson Med       Date:  1995-10       Impact factor: 4.668

Review 6.  Pathology of small artery disease.

Authors:  P T Ostrow; L L Miller
Journal:  Adv Neurol       Date:  1993

7.  Microscopic susceptibility variation and transverse relaxation: theory and experiment.

Authors:  R M Weisskoff; C S Zuo; J L Boxerman; B R Rosen
Journal:  Magn Reson Med       Date:  1994-06       Impact factor: 4.668

Review 8.  Pathogenesis of leukoaraiosis: a review.

Authors:  L Pantoni; J H Garcia
Journal:  Stroke       Date:  1997-03       Impact factor: 7.914

9.  Cerebrospinal fluid proteins in patients with leucoaraiosis: possible abnormalities in blood-brain barrier function.

Authors:  L Pantoni; D Inzitari; G Pracucci; F Lolli; G Giordano; L Bracco; L Amaducci
Journal:  J Neurol Sci       Date:  1993-04       Impact factor: 3.181

10.  Leukoaraiosis and dementia in hypertensive patients.

Authors:  H Yao; S Sadoshima; S Ibayashi; Y Kuwabara; Y Ichiya; M Fujishima
Journal:  Stroke       Date:  1992-11       Impact factor: 7.914

View more
  59 in total

Review 1.  The declining infrastructure of the aging brain.

Authors:  David H Salat
Journal:  Brain Connect       Date:  2011

Review 2.  Pathomechanism of leukoaraiosis: a molecular bridge between the genetic, biochemical, and clinical processes (a mitochondrial hypothesis).

Authors:  Zoltán Szolnoki
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

3.  Ultrasonographic measurement of cerebral blood flow, cerebral circulation time and cerebral blood volume in vascular and Alzheimer's dementia.

Authors:  Stephan J Schreiber; Florian Doepp; Eike Spruth; Ute A Kopp; José M Valdueza
Journal:  J Neurol       Date:  2005-09-12       Impact factor: 4.849

4.  Diastolic blood pressure levels and ischemic stroke incidence in older adults with white matter lesions.

Authors:  Shoshana Reshef; Linda Fried; Norman Beauchamp; Daniel Scharfstein; Daniel Reshef; Steven Goodman
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-10-28       Impact factor: 6.053

5.  Cerebral blood flow by using pulsed arterial spin-labeling in elderly subjects with white matter hyperintensities.

Authors:  A J Bastos-Leite; J P A Kuijer; S A R B Rombouts; E Sanz-Arigita; E C van Straaten; A A Gouw; W M van der Flier; P Scheltens; F Barkhof
Journal:  AJNR Am J Neuroradiol       Date:  2008-05-01       Impact factor: 3.825

6.  Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging.

Authors:  J M Starr; J Wardlaw; K Ferguson; A MacLullich; I J Deary; I Marshall
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-01       Impact factor: 10.154

Review 7.  Obstructive Sleep Apnea and the Brain: a Focus on Gray and White Matter Structure.

Authors:  Andrée-Ann Baril; Marie-Ève Martineau-Dussault; Erlan Sanchez; Claire André; Cynthia Thompson; Julie Legault; Nadia Gosselin
Journal:  Curr Neurol Neurosci Rep       Date:  2021-02-14       Impact factor: 5.081

8.  Cerebrovascular reactivity and white matter integrity.

Authors:  Kevin Sam; Boris Peltenburg; John Conklin; Olivia Sobczyk; Julien Poublanc; Adrian P Crawley; Daniel M Mandell; Lakshmikumar Venkatraghavan; James Duffin; Joseph A Fisher; Sandra E Black; David J Mikulis
Journal:  Neurology       Date:  2016-10-28       Impact factor: 9.910

9.  Cerebral Blood Flow Predicts the Infarct Core: New Insights From Contemporaneous Diffusion and Perfusion Imaging.

Authors:  Shalini Amukotuwa; Matus Straka; Didem Aksoy; Nancy Fischbein; Patricia Desmond; Gregory Albers; Roland Bammer
Journal:  Stroke       Date:  2019-08-29       Impact factor: 7.914

10.  Cognitive decline in metabolic syndrome is linked to microstructural white matter abnormalities.

Authors:  Freddy J Alfaro; Vasileios-Arsenios Lioutas; Daniela A Pimentel; Chen-Chih Chung; Francisco Bedoya; Woo-Kyoung Yoo; Vera Novak
Journal:  J Neurol       Date:  2016-10-11       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.